AstraZeneca posted a stronger‑than‑expected first‑quarter, driven by surging demand for its oncology and rare‑disease portfolio. Revenue reached $15.29 billion, up from $13.59 billion a year earlier, while core earnings also rose. Analysts had penciled in $14.94 billion, leaving the drugmaker ahead of consensus.

Growth stemmed largely from new indications and expanded use of its flagship cancer therapies, which helped offset a modest dip in other segments. When stripped of currency effects, the top line climbed 8%, underscoring the resilience of its pipeline amid a crowded market. Investors welcomed the beat, sending the shares modestly lower after a brief rally.

The results come after AstraZeneca’s strategic push to prioritize high‑margin biologics and diversify beyond its traditional respiratory franchise. By leveraging recent FDA approvals, the company has narrowed its reliance on legacy products and reinforced its position among the world’s top oncology players.

Overall, the quarter demonstrates that targeted drug launches can still lift earnings in a tight macro environment, and the firm now carries a stronger cash cushion to fund ongoing research and potential acquisitions.